Prediction of nonresolving lung condition was analyzed by Cox regression analysis (derivation and validation cohorts)
| Variables . | Univariate analysis . | Multivariate analysis . | ||
|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | |
| Derivation cohort | ||||
| Sex* | 1.281 (0.453-3.523) | .641 | ||
| Age, y | 0.982 (0.399-2.469) | .986 | ||
| Comorbidity (yes/no) | 1.078 (0.358-3.243) | .894 | ||
| Therapy† | 2.298 (0.949-5.565) | .065 | 0.870 (0.344-2.203) | .769 |
| PaO2/FIO2‡ | 0.323 (0.123-0.852) | .022 | 0.856 (0.326-2.248) | .752 |
| INR‡ | 0.995 (0.972-1.019) | .679 | ||
| Bilirubin ‡ | 0.987 (0.934-1.043) | .643 | ||
| CRP‡ | 0.585 (0.231-1.482) | .258 | ||
| Platelets ‡ | 1.183 (0.233-1.678) | .424 | ||
| D-dimer ‡ | 1.183 (0.486-2.879) | .711 | ||
| IL-6§ | 1.454 (0.650-3.250) | .362 | ||
| Angiopoietin-2§ | 3.264 (2.504-4.028) | .001 | 5.332 (1.342-11.769) | .001 |
| Validation cohort | ||||
| Sex* | 0.888 (0.248-3.185) | .856 | ||
| Age, y | 0.998 (0.357-2.789) | .997 | ||
| Comorbidity (yes/no) | 1.028 (0.269-3.931) | .967 | ||
| Therapy† | 2.201 (1.251-3,872) | .006 | 3.437 (1.252-9.340) | .017 |
| PaO2/FIO2‡ | 0.236 (0.066-0.835) | .025 | 1.847 (0.379-9.000) | .447 |
| CRP‡ | — | — | ||
| Platelets‡ | 0.698 (0.248-1.969) | .497 | ||
| D-dimer‡ | 0.570 (0.570-3.729) | .558 | ||
| IL-6§ | — | — | ||
| Angiopoietin-2§ | 2.179 (1.250-5.289) | .002 | 5.250 (2.127-27.809) | .001 |
| Variables . | Univariate analysis . | Multivariate analysis . | ||
|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | |
| Derivation cohort | ||||
| Sex* | 1.281 (0.453-3.523) | .641 | ||
| Age, y | 0.982 (0.399-2.469) | .986 | ||
| Comorbidity (yes/no) | 1.078 (0.358-3.243) | .894 | ||
| Therapy† | 2.298 (0.949-5.565) | .065 | 0.870 (0.344-2.203) | .769 |
| PaO2/FIO2‡ | 0.323 (0.123-0.852) | .022 | 0.856 (0.326-2.248) | .752 |
| INR‡ | 0.995 (0.972-1.019) | .679 | ||
| Bilirubin ‡ | 0.987 (0.934-1.043) | .643 | ||
| CRP‡ | 0.585 (0.231-1.482) | .258 | ||
| Platelets ‡ | 1.183 (0.233-1.678) | .424 | ||
| D-dimer ‡ | 1.183 (0.486-2.879) | .711 | ||
| IL-6§ | 1.454 (0.650-3.250) | .362 | ||
| Angiopoietin-2§ | 3.264 (2.504-4.028) | .001 | 5.332 (1.342-11.769) | .001 |
| Validation cohort | ||||
| Sex* | 0.888 (0.248-3.185) | .856 | ||
| Age, y | 0.998 (0.357-2.789) | .997 | ||
| Comorbidity (yes/no) | 1.028 (0.269-3.931) | .967 | ||
| Therapy† | 2.201 (1.251-3,872) | .006 | 3.437 (1.252-9.340) | .017 |
| PaO2/FIO2‡ | 0.236 (0.066-0.835) | .025 | 1.847 (0.379-9.000) | .447 |
| CRP‡ | — | — | ||
| Platelets‡ | 0.698 (0.248-1.969) | .497 | ||
| D-dimer‡ | 0.570 (0.570-3.729) | .558 | ||
| IL-6§ | — | — | ||
| Angiopoietin-2§ | 2.179 (1.250-5.289) | .002 | 5.250 (2.127-27.809) | .001 |